Long-term surgical outcomes of gastric neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasms.
Gastric cancer
Mixed neuroendocrine-non-neuroendocrine neoplasms
Neuroendocrine carcinoma
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
24 May 2022
24 May 2022
Historique:
received:
08
04
2022
accepted:
06
05
2022
entrez:
24
5
2022
pubmed:
25
5
2022
medline:
27
5
2022
Statut:
epublish
Résumé
Neuroendocrine carcinoma (NEC) and mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) are extremely rare subtypes of gastric cancer. MiNEN is a mix of carcinomatous components and neuroendocrine neoplasm in the same lesion. NEC and MiNEN have a poor prognosis, are difficult to diagnose, and have no established treatment. Herein, we assessed the clinicopathological characteristics and long-term surgical outcomes of gastric NEC and MiNEN patients in our hospital. We retrospectively assessed 1538 patients pathologically diagnosed with gastric cancer and who underwent curative surgical resection at our institution between January 1999 and October 2021. Of these patients, 25 (1.6%) were pathologically diagnosed with neuroendocrine neoplasms. From these 25 patients, we retrospectively analyzed the clinicopathological characteristics and surgical outcomes of 13 (0.8%) patients pathologically diagnosed with NEC or MiNEN. The NEC and MiNEN patients consisted of 11 men and 2 women [mean age, 74 (62-84) years]. The preoperative histological diagnoses were NEC (n = 4) and adenocarcinoma (n = 9). The final pathological diagnoses were large cell neuroendocrine carcinoma (LCNEC; n = 7) and MiNEN (n = 6). Total gastrectomy was the most common surgical procedure (9/13, 69.2%), followed by distal gastrectomy (3/13, 23.1%) and proximal gastrectomy (1/13, 7.7%). Immunohistochemical staining showed 8 CD56-positive patients. All 13 patients were positive for chromogranin A and synaptophysin. The mean Ki-67 value was 64.8 (0-95)%, and the mean mitotic score was 107.9 (0-400). Nine patients survived without recurrence postresection. The median postresection overall survival time was 68.7 (8.0-129) months. The 5-year survival rate was 0.75 ([95% CI] 0.408-0.912). The surgical treatment outcomes of NEC and MiNEN patients were relatively favorable. Although evidence concerning the effectiveness of surgery alone is meager, radical resection as part of multidisciplinary treatment including chemotherapy can potentially improve prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Neuroendocrine carcinoma (NEC) and mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) are extremely rare subtypes of gastric cancer. MiNEN is a mix of carcinomatous components and neuroendocrine neoplasm in the same lesion. NEC and MiNEN have a poor prognosis, are difficult to diagnose, and have no established treatment. Herein, we assessed the clinicopathological characteristics and long-term surgical outcomes of gastric NEC and MiNEN patients in our hospital.
METHODS
METHODS
We retrospectively assessed 1538 patients pathologically diagnosed with gastric cancer and who underwent curative surgical resection at our institution between January 1999 and October 2021. Of these patients, 25 (1.6%) were pathologically diagnosed with neuroendocrine neoplasms. From these 25 patients, we retrospectively analyzed the clinicopathological characteristics and surgical outcomes of 13 (0.8%) patients pathologically diagnosed with NEC or MiNEN.
RESULTS
RESULTS
The NEC and MiNEN patients consisted of 11 men and 2 women [mean age, 74 (62-84) years]. The preoperative histological diagnoses were NEC (n = 4) and adenocarcinoma (n = 9). The final pathological diagnoses were large cell neuroendocrine carcinoma (LCNEC; n = 7) and MiNEN (n = 6). Total gastrectomy was the most common surgical procedure (9/13, 69.2%), followed by distal gastrectomy (3/13, 23.1%) and proximal gastrectomy (1/13, 7.7%). Immunohistochemical staining showed 8 CD56-positive patients. All 13 patients were positive for chromogranin A and synaptophysin. The mean Ki-67 value was 64.8 (0-95)%, and the mean mitotic score was 107.9 (0-400). Nine patients survived without recurrence postresection. The median postresection overall survival time was 68.7 (8.0-129) months. The 5-year survival rate was 0.75 ([95% CI] 0.408-0.912).
CONCLUSION
CONCLUSIONS
The surgical treatment outcomes of NEC and MiNEN patients were relatively favorable. Although evidence concerning the effectiveness of surgery alone is meager, radical resection as part of multidisciplinary treatment including chemotherapy can potentially improve prognosis.
Identifiants
pubmed: 35610656
doi: 10.1186/s12957-022-02625-y
pii: 10.1186/s12957-022-02625-y
pmc: PMC9131531
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
165Informations de copyright
© 2022. The Author(s).
Références
World J Gastrointest Surg. 2014 Apr 27;6(4):77-9
pubmed: 24829627
Gastric Cancer. 2021 Jan;24(1):1-21
pubmed: 32060757
Am J Clin Oncol. 1998 Oct;21(5):458-61
pubmed: 9781599
Gastric Cancer. 2011 Jun;14(2):161-5
pubmed: 21327441
Neuroendocrinology. 2014;100(4):310-6
pubmed: 25342539
Int J Clin Oncol. 2002 Apr;7(2):128-32
pubmed: 12018111
J Cancer Res Clin Oncol. 2020 Aug;146(8):2135-2142
pubmed: 32306127
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Mod Pathol. 2020 Dec;33(12):2602-2613
pubmed: 32461621
Curr Gastroenterol Rep. 2019 Mar 12;21(4):13
pubmed: 30868284
Am J Surg Pathol. 2013 Jul;37(7):949-59
pubmed: 23759931
J Clin Pathol. 2014 Nov;67(11):938-48
pubmed: 25053544
Surg Oncol. 2003 Aug;12(2):153-72
pubmed: 12946486
BMC Cancer. 2020 Aug 18;20(1):777
pubmed: 32811471
Lab Invest. 2003 Jul;83(7):963-71
pubmed: 12861036
Gastric Cancer. 2003;6(4):203-9
pubmed: 14716513